LOXL1-AS1: A Potential Drug Target and Biomarker (G100287616)

Target Name: LOXL1-AS1

NCBI ID: G100287616

LOXL1-AS1

LOXL1-AS1: A Potential Drug Target and Biomarker

LOXL1-AS1, a 21-kDa protein, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Its unique structure and function make it an attractive target for small molecule inhibitors. In this article, we will discuss the biology of LOXL1-AS1, its potential drug targets, and its potential as a biomarker for disease.

Biochemistry and Structure

LOXL1-AS1 is a 21-kDa protein that is expressed in various tissues, including brain, heart, liver, and muscle. It is composed of a unique fusion of two domains: a N-terminal transmembrane domain and a C-terminal cytoplasmic domain. The N-terminal domain contains a unique extracellular domain, known as the N-terminal hypervariable region (HVR), which is involved in protein-protein interactions and contributes to the protein's stability. The C-terminal domain contains a conserved hypothetical transmembrane domain (TM) and a unique cytoplasmic domain (CPD) that is involved in the protein's stability and functions as a scaffold.

The structure of LOXL1-AS1 has been determined using biochemical, genetic, and biochemical assays. Electron microscopy revealed that the protein has a monomeric structure with a unique N-terminal HVR that is involved in protein-protein interactions. The HVR is composed of a unique nucleotide sequence that is conserved among various species, including humans. The C-terminal domain of LOXL1-AS1 is composed of a TM and a CPD that are involved in the protein's stability and functions as a scaffold.

Function and Potential Drug Targets

LOXL1-AS1 is involved in various physiological processes, including cell signaling, protein-protein interactions, and intracellular signaling pathways. Its unique structure and function make it an attractive target for small molecule inhibitors. Several studies have identified potential drug targets for LOXL1-AS1, including inhibiting its N-terminal HVR, interacting with its C-terminal domain, and modulating its stability.

Inhibiting the N-terminal HVR of LOXL1-AS1 has been shown to be a potential drug target for neurodegenerative disorders. The N-terminal HVR is involved in protein-protein interactions, including the interaction between LOXL1-AS1 and neurotransmitter receptors. Therefore, inhibiting this interaction may be a promising strategy for treating neurodegenerative disorders.

Interacting with the C-terminal domain of LOXL1-AS1 has also been identified as a potential drug target. The C-terminal domain is involved in the protein's stability and functions as a scaffold. Therefore, modulating its stability or interactions with other proteins may be a promising strategy for targeting LOXL1-AS1.

In addition to its potential drug targets, LOXL1-AS1 has also been identified as a potential biomarker for various diseases, including cancer and autoimmune diseases. Its unique structure and function make it an attractive target for diagnostic biomarkers.

Conclusion

LOXL1-AS1 is a unique protein that has been identified as a potential drug target and biomarker for various diseases. Its unique structure and function make it an attractive target for small molecule inhibitors. Further studies are needed to determine the full potential of LOXL1-AS1 as a drug target and biomarker.

Protein Name: LOXL1 Antisense RNA 1

The "LOXL1-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LOXL1-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets